For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development | 39,802 | 16,043* | 35,052 | |
| General and administrative | 6,377 | -17,767* | 14,129 | |
| Total operating expenses | 46,179 | -1,724 | 49,181 | |
| Gain from operations | -46,179 | 1,724* | -49,181 | |
| Interest income | 3,944 | 1,011* | 3,444 | |
| Income from transition services agreements | 223 | -1,838* | 1,010 | |
| Change in fair value of participation right liability | 0 | 725* | 0 | |
| Other income (expense) | -94 | 55* | -30 | |
| Total other income, net | 4,073 | -1,497* | 4,424 | |
| Net gain | -42,106 | 227 | -44,757 | |
| Basic EPS | -526.11 | 0.012 | -1.03 | |
| Diluted EPS | -526.11 | 0.012 | -1.03 | |
| Basic Average Shares | 80,032 | 18,798,465 | 43,491,085 | |
| Diluted Average Shares | 80,032 | 18,798,465 | 43,491,085 | |
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)